ÂÜÀòÂÒÂ×

Dr. Antonio Garrido-Montalban is the Vice President of Drug Substance at BlossomHill Therapeutics. Dr. Montalban started his industry career in San Diego as a medicinal chemist at Kemia and has since held positions as the Head of Early-Stage Drug Substance Development at Arena Pharmaceuticals, Executive Director and Site Head of STA Pharmaceutical, a WuXi AppTec Company and Senior Director and Head of Chemical R&D at Arena Pharmaceuticals. Before that, he was an Assistant Professor in the Department of Chemistry at Imperial College London. Notable process chemistry contributions during his tenure at Arena Pharmaceuticals were the approval and launch of BELVIQTM and the development of Etrasimod for which Arena Pharmaceuticals was acquired by Pfizer in 2022 for $6.7 billion. Dr. Montalban has over 29 years of combined industrial and academic experience covering discovery all the way to late-stage development.

Dr. Montalban received his Chemical Engineering degree from the University of Applied Sciences, Darmstadt, Germany and his M.Sc./Ph.D. in Organic Chemistry from the University of East Anglia, Norwich, UK.

Dr. Montalban is an inventor on numerous patents, co-authored over 35 peer-reviewed scientific publications and written a book chapter.